MIT/Harvard synthetic biology startup, innovating in-situ human therapeutics with minimal side effects. Focusing on IBD, autoimmune diseases, and cancers like CRC, PDAC.
Current Status
In vitro, co-culture with mammalian reporter cells.
Problem or Opportunity
Including but not limited to gastrointestinal disorders such as IBD, autoimmune diseases, or even in oncology (CRC, PDAC, etc.).
Solution (product or service)
Vulcan intends to use synthetic biology to engineer bacteria in situ, embedding new functionality into existing and engrafted microbes to deliver therapeutic effects. This is achieved by leveraging engineered, integrative bacteriophages to modify specific bacterial populations long-term, similar to gene therapy.
